Food and Drug Administration

Oncologic Drugs Advisory Committee

Briefing Information

September 7, 2006

Genta Incorporated

Disclaimer

The statements contained in this document(s) are those of the product’s sponsor, not FDA, and FDA does not necessarily agree with the sponsor’s statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

Abraxis Bioscience, Inc Briefing Material for Abraxane (pdf)

FDA

Disclaimer

Portions of this document have been determined to be exempt from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. § 552).
These redacted portions will appear as white space on the screen or on the printed page.

FDA Briefing Material for NDA 21-660 (pdf)